Profile data is unavailable for this security.
About the company
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
- Revenue in SEK (TTM)595.80m
- Net income in SEK-105.30m
- Incorporated1994
- Employees113.00
- LocationOrexo ABP.O. Box 303UPPSALA 751 05SwedenSWE
- Phone+46 187808800
- Fax+46 187808888
- Websitehttps://orexo.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncozenge AB | 0.00 | -11.78m | 107.88m | -- | -- | 7.59 | -- | -- | -1.01 | -1.01 | 0.00 | 1.21 | 0.00 | -- | -- | -- | -55.08 | -- | -59.44 | -- | -- | -- | -- | -- | -- | -2,944.50 | 0.00 | -- | -- | -- | 65.91 | -- | -- | -- |
| Lipidor AB | 87.00k | -13.53m | 113.88m | -- | -- | 6.77 | -- | 1,308.93 | -0.1505 | -0.1505 | 0.0009 | 0.0207 | 0.005 | -- | 0.1843 | -- | -77.12 | -59.41 | -178.11 | -75.10 | -- | -- | -15,550.58 | -643.36 | -- | -- | 0.00 | -- | 73.33 | -20.33 | 72.24 | -- | -- | -- |
| Pila Pharma AB | 1.03m | -6.92m | 130.21m | 0.00 | -- | 44.35 | -- | 125.92 | -0.3165 | -0.3165 | 0.049 | 0.1082 | 0.2602 | -- | 8.21 | 1,034,020.00 | -174.06 | -108.88 | -276.40 | -121.45 | -406.94 | -42.67 | -668.94 | -1,577.64 | -- | -163.35 | 0.00 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
| Vivesto AB | 0.00 | -98.92m | 138.55m | 4.00 | -- | 0.7737 | -- | -- | -0.1839 | -0.1839 | 0.00 | 0.3328 | 0.00 | -- | -- | 0.00 | -39.70 | -- | -43.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | 64.80 | -- | -- | -- |
| Corline Biomedical AB | 17.55m | -6.46m | 171.50m | 14.00 | -- | 1.96 | -- | 9.77 | -0.3005 | -0.3005 | 0.8165 | 4.07 | 0.1729 | -- | 4.69 | 1,349,769.00 | -6.36 | -5.71 | -7.13 | -6.24 | 141.25 | 128.60 | -36.80 | -38.46 | -- | -306.52 | 0.00 | -- | 6.28 | 74.14 | -177.67 | -- | 62.51 | -- |
| Enorama Pharma AB | 5.87m | -41.41m | 181.83m | 5.00 | -- | 6.15 | -- | 30.98 | -0.9211 | -0.9211 | 0.1295 | 0.6408 | 0.1413 | 1.20 | 2.94 | 1,173,800.00 | -99.66 | -73.56 | -147.35 | -104.85 | -32.71 | 43.36 | -705.54 | -557.42 | 2.00 | -29.36 | 0.0094 | -- | -80.17 | -23.71 | -6.15 | -- | -- | -- |
| Lipum AB (publ) | 0.00 | -39.24m | 307.58m | 5.00 | -- | 6.44 | -- | -- | -3.17 | -3.17 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -92.41 | -127.85 | -120.33 | -184.50 | -- | -- | -- | -293,228.70 | -- | -328.75 | 0.1979 | -- | -- | -- | 2.38 | -- | -- | -- |
| Dicot Pharma AB | 233.09k | -50.94m | 373.54m | 3.00 | -- | 13.38 | -- | 1,602.57 | -0.0505 | -0.0505 | 0.0002 | 0.0157 | 0.0054 | 9.26 | 0.079 | 77,696.66 | -117.97 | -- | -144.43 | -- | -19,313.23 | -- | -21,855.92 | -- | 1.98 | -- | 0.00 | -- | 89.43 | -- | -39.05 | -- | -- | -- |
| Orexo AB | 595.80m | -105.30m | 378.35m | 113.00 | -- | -- | -- | 0.635 | -3.05 | -3.05 | 17.28 | -0.7896 | 0.7609 | 1.17 | 2.32 | 5,136,207.00 | -13.45 | -6.41 | -20.81 | -9.99 | 88.28 | 86.76 | -17.67 | -11.83 | 1.47 | -0.7557 | 1.05 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
| Navamedic ASA | 530.94m | 24.07m | 396.87m | 45.00 | 16.49 | 1.64 | 10.19 | 0.7475 | 1.39 | 1.39 | 31.30 | 14.00 | 1.08 | 3.60 | 4.21 | 12,077,510.00 | 4.91 | 0.039 | 7.35 | 0.0635 | 40.04 | 38.33 | 4.53 | 0.038 | 0.8753 | 3.63 | 0.3686 | -- | 33.98 | 22.72 | -88.77 | -2.53 | 59.60 | -- |
| Enzymatica AB (publ) | 44.95m | -55.95m | 436.92m | 16.00 | -- | 4.80 | -- | 9.72 | -0.309 | -0.309 | 0.2485 | 0.3747 | 0.3461 | 1.19 | 8.20 | 2,497,333.00 | -43.08 | -27.36 | -45.77 | -33.98 | 63.99 | 65.08 | -124.47 | -66.12 | -- | -24.43 | 0.2789 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -142.27m | 503.80m | 9.00 | -- | 2.20 | -- | -- | -10.57 | -10.57 | 0.00 | 17.57 | 0.00 | -- | -- | 0.00 | -46.35 | -16.11 | -54.97 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
| Isofol Medical AB (publ) | 0.00 | -34.70m | 565.30m | 3.00 | -- | 5.55 | -- | -- | -0.2164 | -0.2164 | 0.00 | 0.6309 | 0.00 | -- | -- | 0.00 | -24.29 | -66.73 | -28.91 | -88.27 | -- | -- | -- | -1,023.62 | -- | -- | 0.00 | -- | -94.37 | -- | 76.80 | -- | -- | -- |
Data as of Nov 06 2024. Currency figures normalised to Orexo AB's reporting currency: Swedish Krona SEK
7.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ATP Arbejdsmarkedets Till�gspensionas of 31 May 2024 | 1.78m | 5.13% |
| Handelsbanken Fonder ABas of 31 May 2024 | 212.59k | 0.61% |
| Consultinvest Asset Management SGR SpAas of 31 Dec 2023 | 176.45k | 0.51% |
| SEB Investment Management ABas of 30 Sep 2024 | 165.98k | 0.48% |
| Skandia Investment Management ABas of 30 Aug 2024 | 136.46k | 0.39% |
| FCG Fonder ABas of 30 Sep 2024 | 119.47k | 0.34% |
| Storebrand Asset Management ASas of 30 Sep 2024 | 31.45k | 0.09% |
| Nordic Archipelago Investments ABas of 30 Sep 2024 | 12.17k | 0.04% |
| Skandia Fonder ABas of 30 Aug 2024 | 4.77k | 0.01% |
| Evli Fund Management Co. Ltd.as of 30 Aug 2024 | 2.00k | 0.01% |
More ▼
Data from 31 May 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
